(Albany, US) DelveInsight has launched a new report on Muscle Invasive Bladder cancer Pipeline
“Muscle Invasive Bladder cancer Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Muscle Invasive Bladder cancer market. A detailed picture of the Muscle Invasive Bladder cancer pipeline landscape is provided, which includes the disease overview and Muscle Invasive Bladder cancer treatment guidelines. The assessment part of the report embraces in-depth Muscle Invasive Bladder cancer commercial assessment and clinical assessment of the Muscle Invasive Bladder cancer pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Muscle Invasive Bladder cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Bladder neoplasms can arise from any of the four bladder wall layers. They are broadly classified as either epithelial or non-epithelial (mesenchymal), with over 95% being epithelial. Epithelial tumors with differentiation toward normal urothelium are urothelial/ urinary carcinoma (UC). Other types of bladder neoplasms, namely, squamous cell carcinoma, adenocarcinoma, small cell carcinoma and sarcoma account for 2–5% of bladder neoplasms. The majority of UC occurs in males with approximately has two-to-three fold greater incidence as compared to females. UC is the invasion of the basement membrane or lamina propria by neoplastic cells of urothelial origin. The main causative agents of upper tract UC and urinary bladder cancer include cigarette smoking and work-related exposure, while other factors are more specific to the carcinogenesis of upper tract UC (i.e., Balkan endemic nephropathy).
Request for free sample page: – https://www.delveinsight.com/sample-request/muscle-invasive-bladder-cancer-pipeline-insight
Muscle Invasive Bladder Cancer Pipeline development activities
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Muscle Invasive Bladder cancer with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Muscle Invasive Bladder cancer treatment.
- Muscle Invasive Bladder cancer key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Muscle Invasive Bladder cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.
Muscle Invasive Bladder Cancer Pipeline
Urothelial Carcinoma pipeline possesses several potential drugs that are expected to be launched in the near future. Linrodostat (BMS-986205; Bristol-Myers Squibb), Infigratinib (QED Therapeutics) are currently in phase III stage of development for MIBC and UC. While, Sacituzumab govitecan (Immunomedics), NKTR-214 (Nektar Therapeutics/Bristol-Myers Squibb), RX-3117 (Rexahn Pharmaceuticals) and others are in phase II clinical stage. Bristol-Myers Squibb is developing Linrodostat in combination with Nivolumab, which is a selective, potent, once-daily oral IDO1 inhibitor that works to reduce kynurenine production. It has established clinical activity in combination with nivolumab (anti–PD-1) in patients with immunotherapy treatment-naive advanced bladder cancer who had ≥ 1 prior line of therapy (ORR 37%). Current the drug is in phase III stage of clinical development for MIBC.
Infigratinib is an orally administered, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of patients with FGFR-driven diseases, including cholangiocarcinoma (bile duct cancer), urothelial carcinoma (bladder cancer), and achondroplasia, a bone growth disorder in children. Infigratinib is not chemotherapy. QED Therapeutics holds worldwide rights to infigratinib to evaluate its safety and efficacy for multiple FGFR-driven diseases. Currently, the drug is in phase III clinical developmental trial for the adjuvant treatment of subjects with invasive UC with susceptible FGFR3 mutations. In May 2020, the company claimed that it will present data at the American Society of Clinical Oncology 2020 Virtual Scientific Program showing clinical advancement for infigratinib, in both urothelial carcinoma and cholangiocarcinoma (CCA).
Muscle Invasive Bladder Cancer marketed drugs included in the report
- Keytruda: Merck
- Opdivo: Bristol-Myers Squibb
- Tecentriq: Genentech
- Bavencio: Merck
- Imfinzi: AstraZeneca
- Balversa: Janssen
- And many others
Muscle Invasive Bladder Cancer emerging drugs included in the report
- Linrodostat (BMS-986205): Bristol-Myers Squibb
- Infigratinib: QED Therapeutics
- Sacituzumab govitecan (IMMU-132): Immunomedics
- Bempegaldesleukin (NKTR-214): Nektar Therapeutics/Bristol-Myers Squibb
- RX-3117: Rexahn Pharmaceuticals
- ACP-196: Acerta Pharma
- IPI-549: Infinity Pharma
Muscle Invasive Bladder Cancer Report Scope
- The Muscle Invasive Bladder cancer report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Muscle Invasive Bladder cancer across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Muscle Invasive Bladder cancer therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Muscle Invasive Bladder cancer research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Muscle Invasive Bladder cancer.
Download free sample page: – https://www.delveinsight.com/sample-request/muscle-invasive-bladder-cancer-pipeline-insight
Table of content
1. Report Introduction
2. Muscle Invasive Bladder cancer
3. Muscle Invasive Bladder cancer Current Treatment Patterns
4. Muscle Invasive Bladder cancer – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Muscle Invasive Bladder cancer Late Stage Products (Phase-III)
7. Muscle Invasive Bladder cancer Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Muscle Invasive Bladder cancer Discontinued Products
13. Muscle Invasive Bladder cancer Product Profiles
14. Muscle Invasive Bladder cancer Key Companies
15. Muscle Invasive Bladder cancer Key Products
16. Dormant and Discontinued Products
17. Muscle Invasive Bladder cancer Unmet Needs
18. Muscle Invasive Bladder cancer Future Perspectives
19. Muscle Invasive Bladder cancer Analyst Review
21. Report Methodology
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States